Defining the Extent and Grade of Prostate Cancer Using Dynamic Contrast Enhanced Diffusion Weighted and BOLD MRI

• Register: ClinicalTrials.gov
• Last refreshed on: 16 December 2017
• Main ID: NCT00242112
• Date of registration: 18/10/2005
• Prospective Registration: No
• Primary sponsor: University Health Network, Toronto
• Public title: Defining the Extent and Grade of Prostate Cancer Using Dynamic Contrast Enhanced Diffusion Weighted and BOLD MRI
• Scientific title: Defining the Extent and Grade of Prostate Cancer Using Dynamic Contrast Enhanced Diffusion Weighted and BOLD MRI
• Date of first enrolment: June 2005
• Target sample size: 31
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT00242112
• Study type: Interventional
• Study design: Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).
• Phase: N/A

Countries of recruitment

Canada

Contacts

• Name: Masoom Haider, MD
• Affiliation: University Health Network, Toronto

Key inclusion & exclusion criteria

Patients will be recruited from the University Health Network (UHN). Eligible patients will
be undergoing radical prostatectomy for prostate cancer at UHN. Patients with a
contraindication to MRI or MRI contrast agents, claustrophobia, renal failure, allergy to
MRI contrast agents, or prior hormonal therapy or radiation therapy for prostate cancer, a
biopsy within 3 weeks of the surgical date or active prostatitis will be excluded.



Age minimum: 18 Years
Age maximum: N/A
Gender: Male

Health Condition(s) or Problem(s) studied

Prostate Cancer

Intervention(s)

Procedure: MRI Prostate

Primary Outcome(s)

Extent and Grade of Prostate Cancer Using MRI [Time Frame: Imaging followed by pathology analysis]

Secondary ID(s)

05-0387-CE

Source(s) of Monetary Support

Please refer to primary and secondary sponsors